Type 2 Diabetes Subgroups, Risk for Complications, and Differential Effects Due to an Intensive Lifestyle Intervention
- PMID: 33707304
- PMCID: PMC8132317
- DOI: 10.2337/dc20-2372
Type 2 Diabetes Subgroups, Risk for Complications, and Differential Effects Due to an Intensive Lifestyle Intervention
Abstract
Objective: We reevaluated the Action for Health in Diabetes (Look AHEAD) intervention, incorporating diabetes subgroups, to identify whether intensive lifestyle intervention (ILI) is associated with differential risk for cardiovascular disease (CVD) by diabetes subgroup.
Research design and methods: In the Look AHEAD trial, 5,145 participants, aged 45-76 years, with type 2 diabetes (T2D) and overweight or obesity were randomly assigned to 10 years of ILI or a control condition of diabetes support and education. The ILI focused on weight loss through decreased caloric intake and increased physical activity. To characterize diabetes subgroups, we applied k-means clustering to data on age of diabetes diagnosis, BMI, waist circumference, and glycated hemoglobin. We examined whether relative intervention effects on the trial's prespecified CVD outcomes varied among diabetes subgroups.
Results: We characterized four subgroups related to older age at diabetes onset (42% of sample), poor glucose control (14%), severe obesity (24%), and younger age at diabetes onset (20%). We observed interactions (all P < 0.05) between intervention and diabetes subgroups for three separate composite cardiovascular outcomes. Randomization to ILI was associated with increased risk for each cardiovascular outcome only among the poor-glucose-control subgroup (hazard ratio >1.32). Among the three other diabetes subgroups, ILI was not associated with increased risk for CVD.
Conclusions: Among overweight and obese adults with T2D, a lifestyle intervention was associated with differential risk for CVD that was dependent on diabetes subgroup. Diabetes subgroups may be important to identify the patients who would achieve benefit and avoid harm from an ILI.
Trial registration: ClinicalTrials.gov NCT00017953.
© 2021 by the American Diabetes Association.
Figures


References
-
- American Diabetes Association . Introduction: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S1–S2 - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
- U01 DK057151/DK/NIDDK NIH HHS/United States
- U01 DK057154/DK/NIDDK NIH HHS/United States
- U01 DK056992/DK/NIDDK NIH HHS/United States
- U01 DK057171/DK/NIDDK NIH HHS/United States
- U01 DK057182/DK/NIDDK NIH HHS/United States
- U01 DK057002/DK/NIDDK NIH HHS/United States
- U01 DK057177/DK/NIDDK NIH HHS/United States
- M01 RR001066/RR/NCRR NIH HHS/United States
- U01 DK057078/DK/NIDDK NIH HHS/United States
- U01 DK057008/DK/NIDDK NIH HHS/United States
- U01 DK057149/DK/NIDDK NIH HHS/United States
- P30 DK048520/DK/NIDDK NIH HHS/United States
- U01 DK057135/DK/NIDDK NIH HHS/United States
- UL1 RR024153/RR/NCRR NIH HHS/United States
- P30 DK046204/DK/NIDDK NIH HHS/United States
- M01 RR002719/RR/NCRR NIH HHS/United States
- M01 RR000056/RR/NCRR NIH HHS/United States
- U01 DK057219/DK/NIDDK NIH HHS/United States
- K23 DK110341/DK/NIDDK NIH HHS/United States
- U01 DK057136/DK/NIDDK NIH HHS/United States
- U01 DK057131/DK/NIDDK NIH HHS/United States
- M01 RR000051/RR/NCRR NIH HHS/United States
- U01 DK056990/DK/NIDDK NIH HHS/United States
- UL1 RR025758/RR/NCRR NIH HHS/United States
- U01 DK057178/DK/NIDDK NIH HHS/United States
- M01 RR001346/RR/NCRR NIH HHS/United States
- P30 DK017047/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical